Home›Companies›Healthcare›Neosoma

Neosoma, Inc.

Brain tumor imaging software for doctors treating patients with brain cancer.

Updated Nov 11, 2026·Latest SEC filing Mar 27, 2026·Suggest an edit

About Neosoma

Neosoma is a private company based in Groton, Massachusetts. It has reported $10,175,579 raised in five offerings on Form D since November 2020. Its chief executive is Kenneth Kolodziej.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Mar 18, 2026Mar 27, 2026$3,517,368of $5.8M target52$67,642EquityRule 506(b)Form D ↗
Dec 24, 2024Jan 8, 2025$345,000of $800K target5$69,000Debt, OptionsRule 506(b)Form D ↗
Jul 11, 2024Jul 26, 2024$5,053,211of $5.7M target54$93,578Equity, Options, Securities on exerciseRule 506(b)Form D ↗
Aug 16, 2023Aug 31, 2023amended Feb 13, 2024$1,185,000of $3.1M target15$79,000Debt, OptionsRule 506(b)Form D/A ↗1 earlier filing
Nov 5, 2020Nov 20, 2020$75,000of $750K target2$37,500Debt, OptionsRule 506(b)Form D ↗
Total, five offerings$10,175,579

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Neosoma's Form D filed Mar 27, 2026.

MH
Michael Hill
Chief Technology Officer
Kenneth Kolodziej
Kenneth Kolodziej
Co-Founder and Chief Executive Officer, director

Earlier filings also listed Oleg Ikhelson (director, last listed Jan 2025), John Liedtky (executive officer, last listed Jan 2025), Deborah Millin (director, last listed Jan 2025) and Aly Abayazeed (executive officer and director, last listed Feb 2024).

Sources

  1. SECNeosoma, Inc. Form D, filed Aug 31, 2023
  2. SECNeosoma, Inc. filing history
  3. CompanyNeosoma team
  4. ResearchFDA: Neosoma Brain Mets